---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-003048"
form_type: "8-K"
ticker: null
cik: "0000727207"
company_name: "Accelerate Diagnostics, Inc"
filed_at: "2023-01-11T23:59:59+00:00"
generated_at: "2026-06-20T16:44:43.307293+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Accelerate Diagnostics receives Nasdaq deficiency notice for bid price below $1.00

## Summary
- Deficiency letter received Jan 5, 2023; stock closed below $1.00 for 30 consecutive business days.
- Must regain compliance by July 5, 2023; bid price must close at $1.00+ for 10 consecutive days.
- If not compliant by deadline, may qualify for additional 180 days or face delisting.
- Company evaluating options including a potential reverse stock split to cure deficiency.
- No assurance that compliance will be regained or that any remedy will succeed.

## SEC filing metadata
- accession: 0001104659-23-003048
- form_type: 8-K
- cik: 0000727207
- company_name: Accelerate Diagnostics, Inc
- filed_at: 2023-01-11T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/727207/000110465923003048/0001104659-23-003048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/727207/000110465923003048/tm232435d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-003048
- JSON: https://secwatch.observer/filing/0001104659-23-003048.json
- Plain text: https://secwatch.observer/filing/0001104659-23-003048.txt

## Key facts
- Listing & Compliance Notices
  Accelerate Diagnostics, Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: January 5, 2023, Accelerate Diagnostics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calend
  evidence_url: https://www.sec.gov/Archives/edgar/data/727207/000110465923003048/0001104659-23-003048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.